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1. Origin 
Hypoglycin A, P_(methylenecyclopropyl)alanine, is 
a non-protein amino acid first isolated [l] from the 
unripe fruit of the ackee, Blighia sapida, a tree much 
cultivated in Jamaica where the fleshy aril constitutes 
an important item of diet, particularly of the lower 
income groups. The unripe ackee aril may contain 
around 1 mg of hypoglycin per g wet weight and the 
seeds two to three times as much, but as the fruit 
ripens the content of the aril decreases to less than 
0.01% of the amino acid [2] . Hypoglycin is found in 
the seeds both as the free amino acid and the y-glu- 
tamyl dipeptide conjugate, hypoglycin B [3] . It is 
also found in ripe sycamore fruits (Acer pseudoplata- 
nus) [4] and as the major component of the free 
amino acid pool in the seeds of Billia hippocastanum 
of Costa Rica [S] . 
Hypoglycin possesses both a cyclopropane ring and 
a methylene group, neither of which are found in any 
protein amino acids. Fruits of species related to ackee 
and some others contain several varieties of non- 
protein amino acids with cyclopropane rings, e.g. OL- 
(methylenecyclopropyl)glycine from Litchi chinensis 
and Acer genus as well as B. sapida [3,6,7], (3- 
(methylenecyclopropyl)~(3-methylalanine from Aescu- 
lus californica [8] and cis- and trans-cu-(carboxycyclo- 
propyl)glycine from the seeds of A. parvifzora and 
A. pavia and B. sapida [9]. Methylene groups in non- 
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protein amino acids are also quite widespread in the 
plant world [lo] . 
Little is known of the pathway of hypoglycin 
synthesis. [U-l4 C]Acetate and [methyl-l4 Clmethio- 
nine have been found to act as precursors in sycamore 
and ackee fruits [7]. It is possible that a linear C6 
skeleton is first formed and the methyl C of methio- 
nine becomes the third C of the cyclo.propane ring. 
2. Toxicity 
Hypoglycin was first isolated and gained promi- 
nence as the toxic, and probably causative, agent 
involved in Jamaican ‘vomiting sickness’ (reviewed in 
[ 11, 121). This condition is characterised by a sudden 
onset of vomiting several hours after a meal contain- 
ing unripe ackees, and development of a profound 
hypoglycaemia which may lead eventually to convul- 
sions, coma and death. Malnourished individuals and 
children appear to be the most susceptible victims. 
Fatalities are still occasionally reported, though, with 
improved educational and nutritional standards, the 
incidence has declined in the years since the last 
major outbreak in Jamaica in 195 1. Treatment with 
thiamine, riboflavin or B vitamin complex is reported- 
ly beneficial - in fact ackees have been described as 
an antimetabolite with respect to riboflavin [ 131. 
Intravenous glucose relieves the hypoglycaemia. In 
the cases that the author has seen reported both 
ackees and rum have been taken. It is an interesting 
question (section 6.2.) whether alcohol may aggravate 
the effects of hypoglycin. Although many of the 
clinical symptoms of ackee poisoning can be repro- 
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duced in experimental animals - rats, monkeys, 
guinea pigs, cats, dogs, rabbits, mice, there are no 
reported tests of hypoglycin action in man. 
3. Chemical synthesis 
Complete chemical synthesis of hypoglycin was 
first reported by Carbon et al. [14] in a six stage 
procedure starting from 2-bromopropene, forming 
the cyclopropane ring by treatment of this with ethyl 
diazoacetate. Subsequently Black and Landor [ 15, 
161 introduced a three stage synthesis (fig. 1) starting 
from 1-bromobuta-2,3-diene (I) and diethyl l-formyl- 
aminomalonate which condense in the presence of 
sodium hydride to give diethyl buta-2,3-dienylformyl- 
aminomalonate (II). Treatment of this with di-iodo- 
methane and a Zn/Cu couple resulted in addition of 
methylene to the non-terminal double bond to give 
the crude cyclopropane (III), which was hydrolysed 
in alkali, then decarboxylated in acid to yield hypo- 
glycin (IV), whose configuration was established to 
be that of the natural product. Virtually all work on 
the metabolic actions of hypoglycin has been carried 
out with material from natural sources. 
Von Holt [ 171 prepared [ l-l4 Clhypoglycin by 
treating methylenecyclopropane-acetaldehyde with 
[ l4 Clcyanide and ammonium carbonate to form the 
corresponding hydantoin which was subsequently 
saponified to the amino acid. 
4. Purification 
One of the inevitable problems about use of the 
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natural product is its purity. The usual procedure for 
extraction of hypoglycin is by boiling ground seeds or 
ackee arils with water or aqueous ethanol followed by 
isolation of the neutral amino acids on ion exchange 
resins [ 1,2] . On concentration, hypoglycin as the 
most abundant and a poorly soluble acid, crystallises 
out and can be purified by recrystallisation. It seems 
clear however that hypoglycin prepared by these 
means is far from pure and there may be contamina- 
tion by other amino acids. These can be recognised 
by paper chromatography or, more accurately, by the 
usual Moore and Stein type amino acid analyser. Sam- 
ples analysed in this manner have been shown to be 
contaminated by valine, isoleucine, phenylalanine, 
tyrosine, methionine and other unidentified products 
[ 181. However one of the most likely contaminants 
of hypoglycin is recognised to be leucine which is 
particularly difficult to resolve - either to recognise 
in the presence of hypoglycin or to separate. Patrick 
[ 191 reported the impossibility of resolving leucine 
and hypoglycin on paper in 17 different solvent sys- 
tems tested, and with the standard citrate buffers on 
ion exchange columns hypoglycin and leucine appear 
to run with identical mobilities under conditions in 
which valine, isoleucine, norleucine and leucine are all 
resolvable [ 18,20, 2 I] . It may be that with lithium 
citrate buffers, which are claimed to improve resolu- 
tion of certain amino acid overlaps [22], or with an 
older elution procedure using HCl [23] , a separation 
of leucine and hypoglycin is possible. Although there 
are claims for procedures by which leucine and hypq- 
glycin can be separated and separately identified [24, 
251, the surest way at present of preparing hypo- 
glycin free of leucine appears to be to make it from 
hypoglycin B, which can be unequivocally separated 
from leucine, when the hypoglycin liberated on hy- 
drolysis is readily separable from the glutamate [20, 
261. However, only a limited amount of hypoglycin 
has been prepared by this means to date. 
The methylene group of hypoglycin is, of course, 
readily reduced, e.g. by sodium borohydride, giving a 
variety of products. It is also attacked by halogens. 
Patrick [ 191 found that on iodination hypoglycin 
was converted to a derivative now readily separable 
from leucine by paper chromatography, thus allowing 
him to estimate the low extent of contamination of 
his hypoglycin preparation by leucine. More recently, 
Fincham [21] has developed a procedure using the 
auto-analyser for measuring hypoglycin and leucine in 
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the presence of each other. This involves running two 
samples - the first estimates leucine plus hypoglycin. 
The second sample is first treated under acid condi- 
tions with bromine after which analysis of the re- 
maining leucine is made, with the difference being 
hypoglycin. Some hypoglycin samples so analysed 
have contained up to 20% leucine [ 181. Unequivocal 
detection and estimation of hypoglycin in extracts of 
ackee has recently become a problem of commercial 
importance in Jamaica since a lucrative export trade 
of canned ackees to Europe and North America is 
threatened by an American FDA requirement that 
the hypoglycin content of the canned product be 
stated. 
5. Degradation 
Hypoglycin, as its name implies, produces hypogly- 
caemia in responsive species, but there is usually a 
delay before the blood sugar level begins to fall. This 
suggests that it may be a metabolite of hypoglycin 
that exerts the major toxic actions. 
When injected into rats hypoglycin is rapidly dis- 
tributed to the various organs and it is not obviously 
concentrated in any one [27], a pattern such as one 
might expect for a branched chain amino acid. There 
is some loss of hypoglycin in the urine but most of it 
is metabolised. Whether the pattern of distribution is 
the same when ingested as opposed to being injected 
has not been investigated. 
Degradation of hypoglycin in rats, and presumably 
man, follows the pattern of catabolism of the branch- 
ed chain amino acids. It is first deaminated by trans- 
cH3bi-CH2-CH~NW+COOH 
CH3’ 
I 
Leucine 
CH3\ 
CH3 
,CH-CH2-CO-COOH 
I 
cb\ 
+ 
CH3 
,CH-CH2-CO-S-CoA 
I 
lsovaleryi-CoA 
CY 
CH3 
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Fig. 2. 
amination to yield methylenecyclopropylpyruvate 
(MCPP) which then undergoes oxidative decarboxyl- 
ation to form methylenecyclopropylacetyl-CoA (fig. 
2). Rats injected with [ l-l4 Clhypoglycin excrete 60% 
of the label within 2 hours as l4 Co2 [ 171. Presum- 
ably hydrolysis of the ester is possible and Tanaka et 
al. [28] have shown that, after a single dose of hypo- 
glycin, plasma concentrations of methylenecyclo- 
propylacetate (MCPA) rise to a maximum by 4-5 hr 
and then slowly decline. It is not known what pro- 
portion of hypoglycin degradation normally occurs in 
the liver - skin for example appears to be able to 
metabolise it [29] and extrahepatic tissues are a 
major site of branced chair amino acid catabolism. 
Whether MCPA can be degraded further has not been 
shown. A major portion of it is excreted as the gly- 
tine conjugate MCPA-glycine [28]. 
6. Metabolic actions 
The toxic effects of hypoglycin can result from 
actions either of the amino acid itself or of any of its 
degradation products. Early work (reviewed in [ 1 I] 
and [30] ) suggested that hypoglycin interferes with 
utilisation of long chain fatty acids. Their oxidation is 
inhibited and the blood concentration rises, as does 
the fat content of the liver. A decrease in fatty acid 
metabolism will lead to increased utilisation of glu- 
cose. As a result of a disturbance of hepatic mito- 
chondrial function [3 1,321 gluconeogenesis may be 
decreased. There is therefore rapid depletion of glyco- 
gen reserves and hypoglycaemia follows. The marked 
s13.5 
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effects of hypoglycin on the blood sugar level and on is reduced such that it is limiting, then an inhibitory 
fat metabolism thus strongly suggest an inhibition of influence of hypoglycin, as of other amino acids, does 
Poxidation of fatty acids by MCPP or MCPA as an become apparent. The molar ratios of hypoglycin to 
important site of action. More recently it has become leucine required of course are far in excess of any- 
evident that the effects of hypoglycin may be more thing likely to be encountered in the cell and the 
diverse. effect is unlikely to be of physiological significance. 
6.1. Effects of hypoglycin itself 6.2. Inhibition of fatty acid oxidation 
As an analogue of leucine hypoglycin might be 
expected to compete with leucine in various reac- 
tions. Fowden has found [33] that the lower homo- 
logue of hypoglycin, methylenecyclopropylglycine, 
inhibits growth of seedlings through antagonising 
utilisation of leucine. Anderson and Fowden [26] 
also found that hypoglycin would interact with leu- 
cyl-tRNA synthetase from A. hippocastanum as 
judged by pyrophosphate exchange. The Km of the 
enzyme towards hypoglycin was roughly 80-fold 
higher and the Vmax about half that obtainable with 
leucine. Moreover hypoglycin in loo-fold excess 
depressed the activity observable with leucine alone. 
Hypoglycin did not affect activity of phenylalanyl- 
tRNA synthetase from the same source. As Anderson 
and Fowden concluded, a study of the substrate 
specificity of mammalian leucyl-tRNA synthetase 
with respect to hypoglycin would be of interest. This 
has not been done. However the present author has 
looked at the influence of hypoglycin on the incorpo- 
ration of leucine into protein by ribosomes isolated 
from rat liver. The results indicate how important it is 
to know the purity of the hypoglycin samples em- 
ployed in study of its actions, for all samples of hypo- 
glycin tested except one showed marked inhibition of 
leucine incorporation and some also inhibited incor- 
poration of phenylalanine. The only sample that at 
first appeared to have no inhibitory influence on 
incorporation of either amino acid when present even 
at concentration ratio of 100 : 1 was one kindly 
provided by Professor L. Fowden and which had been 
prepared by hydrolysis of hypoglycin B (section 4). 
The inhibitory influence of the other samples thus 
seems likely to be a result of impurities - a point 
confirmed by amino acid analysis. The above experi- 
ments however were carried out under conditions in 
which the concentration of activating enzymes were 
not rate limiting in amino acid incorporation. Further 
results suggest hat if the quantity of cell sap fraction 
Von Holt et al. [31] proposed that a major action 
of hypoglycin is to interfere with oxidation of fatty 
acids. The circumstantial evidence for this proposal 
was 1) the rise in the serum free fatty acids and fatty 
infiltration of the liver after hypoglycin administra- 
tion, 2) hypoglycin increased glucose oxidation in the 
intact animal, 3) liver glycogen was depleted after 
hypoglycin treatment though its synthesis or break- 
down appeared unaffected, 4) riboflavin administra- 
tion prevented the effects of hypoglycin. 
More direct evidence for the site of action of hypo- 
glycin and its derivatives is that production of COZ 
by hypoglycin-poisoned rats is diminished as a result 
of reduction in fatty acid oxidation [3 11. MCPA 
inhibits oxidation of Ci 2 -Cr s fatty acids by isolated 
mitochondria, though not that of shorter chain acids. 
Acetoacetate production from palmitate is reduced, 
as also is acetate incorporation into cholesterol. It 
seems possible that MCPA as the CoA derivative 
inhibits an enzyme within the fatty acid oxidation 
spiral, most probably a flavin-nucleotide-dependent- 
acyl-CoA dehydrogenase. The capacity of riboflavin 
to prevent development of hypoglycin poisoning 
would be consistent with this, though the precise 
manner in which it would relieve inhibition of an 
enzyme has yet to be established. 
Further understanding of possible ways in which 
MCPA might influence fatty acid oxidation has been 
gained by the use of 4-pentenoate. This short chain 
acid is the simplest of a series of unsaturated hypogly- 
caemic fatty acids related to hypoglycin, and likewise 
inhibits fatty acid oxidation (discussed in refs. [34] 
and [35]). It seems clear that formation of pente- 
noyl-CoA is necessary for inhibition, but Bressler et 
al. [ 1 l] did not find pentenoylCoA to be an inhibi- 
tor of acyl-CoA dehydrogenase. A possible mechanism 
by which MCPA (and pentenoate) might inhibit fatty 
acid oxidation is in effect by a lethal synthesis - 
formation of MCPA-CoA which is only slowly, if at 
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all, further metabolised and depletes available CoA 
resources. Alternatively an interaction with acyl-CoA 
carnitine transferase would lead to accumulation of 
the MCPA-carnitine ester, which in turn would have 
the effect of depleting available carnitine. This action 
might interfere with entry of long chain, though not 
of the shorter chain, fatty acids into the mitochon- 
drion and so explain why oxidation of longer chain 
acids is more susceptible to inhibition than is that of 
the shorter (though an alternative explanation of this 
phenomenon is that the shorter chain fatty acids 
compete effectively with the inhibitor for the acyl- 
CoA ligase [35]). 
Bressler and coworkers [36] observed that addi- 
tion of CoA and carnitine together would overcome 
inhibition of fatty acid oxidation produced in pigeon 
liver homogenates and mitochondria by pentenoate, 
and under these conditions there was accumulation of 
pentenoyl-carnitine and acrylyl-carnitine. Similar 
results have not been published for MCPA. Sherratt 
[29,34,35] has questioned the validity of this 
‘sequestration’ hypothesis since a number of non- 
hypoglycaemic compounds can also affect intramito- 
chondrial CoA concentrations. He has been unable to 
overcome hypoglycaemic effects of either hypoglycin 
or pentenoic acid in mice with carnitine, and has 
stressed the point that hypoglycaemia may result 
from or be aggravated by the hypothermia induced 
by both acids [34,37]. He finds [38] that 2,4-penta- 
dienoyl-CoA formed from 4-pentenoate is a strong 
inhibitor of /I-ketoacyl-CoA thiolase. Pentenoic acid 
and a number of other fatty acids with ring-contain- 
ing structures have been studied as possible oral hypo- 
glycaemic agents [30], but they are all, not surpris- 
ingly, too toxic for clinical use. 
Inhibition of utilisation of fatty acids is to be 
expected to produce in vivo a greater demand for 
glucose. This demand can in part be supplied by 
gluconeogenesis. An inhibition by hypoglycin of this 
process [39] would aggravate hypoglycaemic effects, 
particularly in fasting. As with fatty acid metabolism 
MCPP and MCPA are likely to be toxic agents that 
could interfere with glucose production and this has 
been demonstrated recently with kidney cortex slices 
[40]. Pentenoate also reduces glucose formation by 
kidney slices [41] and markedly depresses gluconeo- 
genesis from alanine and pyruvate in the perfused rat 
liver [42,43]. This inhibition seems, in the liver, to 
be the consequence of diminution of the cytoplasmic 
NADH concentration resulting from decreased fatty 
acid oxidation, which leads to a fall in triose .phos- 
phate formation [42,43]. A marked decrease in 
acetyl-CoA concentrations, with consequent dimin- 
ished activation of pyruvate carboxylase, also occurs. 
Addition of ethanol restored glucose formation by 
raising the NADH level of the cytoplasm [42]. It 
would be interesting to know how pentenoate affects 
gluconeogenesis from lactate which itself generates 
NADH. Moreover ethanol in the malnourished inhib- 
its oxidation of lactate and can promote hypoglycae- 
mia [44]. It is therefore an interesting question 
whether alcohol, as rum or otherwise, taken with 
unripe ackees may aggravate or ameliorate the ensu- 
ing hypoglycin poisoning. 
Despite inhibiting hepatic ketone body production 
[3 l] , intramuscular administration of hypoglycin 
appears to raise blood levels of ketones and particu- 
larly of acetoacetate [45]. The most likely explana- 
tion of this phenomenon is that hypoglycin, like 
leucine, is degraded extrahepatically as well as in the 
liver and that MCPA so formed can interfere with 
acetoacetate utilisation, possibly through sequestra- 
tion of CoA. 
6.3. Inhibition of leucine catabolism 
In addition to their effects on fatty acid metabol- 
ism the catabolic products of hypoglycin have more 
recently been implicated as inhibitors of the normal 
metabolism of leucine and lysine. Leucine catabolism 
involves first deamination to form &ketoisocaproate 
followed by oxidative decarboxylation to yield iso- 
valeryl-CoA (fig. 2). This then undergoes a&dehydro- 
genation to form /I-methylcrotonyl-CoA. There is an 
inborn error of metabolism, isovaleric acidaemia, in 
which isovaleric acid accumulates in blood in large 
amounts. This disorder (which is analogous to another 
inborn error of leucine catabolism, the maple syrup 
urine disorder) is thought to arise through a deficien- 
cy of the specific flavin-containing dehydrogenase, 
namely isovaleryl-CoA dehydrogenase, required to 
dehydrogenate isovaleryl-CoA [46]. Tanakaet al. 
[47] find that MCPP inhibits oxidation of leucine by 
liver slices. They have proposed that inhibition of iso- 
valeryl-CoA dehydrogenase, presumably by the deriv- 
ative MCPA-CoA acting as a competitive inhibitor, is a 
major site of action of hypoglycin. 
Administration of hypoglycin causes a very marked 
s137 
Volume 40, Supplement FEBS LETTERS 23 March 1974 
rise in blood levels of isovalerate (and ar-methylbuty- 
rate - a structural isomer) and also a marked increase 
in the urinary excretion of N-isovalerylglycine [48, 
491, a situation similar to that encountered in here- 
ditary isovaleric acidaemia characterised by lack of 
hepatic isovaleryl-CoA dehydrogenase. By compari- 
son with leucine, hypoglycin has little effect on oxid- 
ation of valine and isoleucine [47,.50]. Isovaleric 
acid, like other short chain fatty acids, is neurotoxic 
[5 1,521 and can produce symptoms of depression, 
vomiting and ataxia [28]. Tanaka and colleagues 
[28] suggest hat it is isovaleric acid poisoning rather 
than interference with P-oxidation that is responsible 
for many of the symptoms of hypoglycin poisoning. 
Administration of hypoglycin to rats is also found 
to promote excretion of glutarate, adipate and a num- 
ber of longer chain dicarboxylic acids [47]. Glutarate 
is an intermediate of lysine breakdown and is normal- 
ly metabolised by glutaryl-CoA dehydrogenase which 
is presumably subject to inhibition like isovaleryl- 
CoA dehydrogenase by MCPA-CoA. Glutarate is 
nephrotoxic [53,54] and may be the cause of histo- 
logical changes observed in kidneys of patients suffer- 
ing from vomiting sickness. The origin of the adipate 
and other acids is less clear. 
7. Teratogenic effects 
The capacity of hypoglycin to produce nephro- 
and particularly neurotoxic agents may well be part 
explanation of the teratogenic effects of the amino 
acid noted by Persaud [55]. Hypoglycin given to 
pregnant rats from the first to the sixth day induced a 
significant incidence of congenital anomalies and 
foetal resorption, an effect that was markedly aggra- 
vated when leucine was given simultaneously. In fact 
administration of leucine alone was teratogenic. 
Whilst a hypoglycaemia produced by hypoglycin in 
the mother may well have an effect on the foetal 
metabolism, it seems unlikely that hypoglycin would 
be affecting foetal fat metabolism directly, if only 
because foetal tissue is characterised by a high glyco- 
1Jrtic dependence. However, the presence of an abnor- 
mally high plasma concentration of either MCPP or 
MCPA or of isovaleric acid might well be expected to 
have a deleterious influence on embryonic develop- 
ment. The simultaneous administration of carnitine 
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with the hypoglycin did not diminish foetal malform- 
ation. Administration of riboflavin however did. On 
the other hand riboflavin had no effect on leucine 
induced abnormalities. It is interesting to note that 
the mouse by comparison with the rat is less sensitive 
to hypoglycin both as regards hypoglycaemia and 
teratogenic effects [ 11, 561. It would be of value to 
know whether there are significant differences be- 
tween the two species in the circulating levels of iso- 
valeric acid in response to the various agents. 
8. Conclusions 
Clearly the sites of action of hypoglycin are multi- 
ple and it is the metabolites that exert the major tox- 
ic actions. However the precise details of how fatty 
acid oxidation is inhibited remain to be worked out. 
There is also scope for explanation of species differ- 
ences in sensitivity and response. Maybe further work 
on hypoglycin will lead to clearer understanding of 
the reason for the remarkably similar chromato- 
graphic properties of leucine and hypoglycin, and to 
more detailed knowledge of the enzymology of 
Poxidation and intermediary metabolism in various 
species. 
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